Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future
protection of individuals and populations against SARS-CoV-2. Moreover, passively …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern
(VOCs), especially the latest Omicron, have exhibited severe antibody evasion. Broadly …

The omicron variants of SARS-CoV-2 have substantial ability to escape infection-and
vaccine-elicited antibody immunity. Here, we investigated the extent of such escape in nine …

The interactions between antibodies, SARS-CoV-2 and immune cells contribute to the
pathogenesis of COVID-19 and protective immunity. To understand the differences between …

One major limitation of neutralizing antibody-based COVID-19 therapy is the requirement of
costly cocktails to reduce emergence of antibody resistance. Here we engineer two …

Development of effective therapeutics for mitigating the COVID-19 pandemic is a pressing
global need. Neutralizing antibodies are known to be effective antivirals, as they can be …

Many individuals mount nearly identical antibody responses to SARS-CoV-2. To gain insight
into how the viral spike (S) protein receptor-binding domain (RBD) might evolve in response …

Natural infection of SARS-CoV-2 in humans leads to the development of a strong
neutralizing antibody response, however the immunodominant targets of the polyclonal …

Antibodies play a central role in the immune defense against SARS-CoV-2. Emerging
evidence has shown that nonneutralizing antibodies are important for immune defense …

Many SARS-CoV-2 neutralizing antibodies (nAbs) lose potency against variants of concern.
In this study, we developed 2 strategies to produce mutation-resistant antibodies. First, a …